Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about whether a doctor is needed for injections of a product called SCUBE3 for hair loss. No specific treatments were discussed.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

New hair loss treatment called scube3 discussed with mixed opinions. Concerns about pharmaceutical companies preferring repetitive treatments over cures due to profit.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.